Financial Performance: Mesoblast Limited reported a 191% increase in revenue from cell therapy products, totaling US$17.2 million for the year ending June 30, 2025, driven primarily by the successful launch of Ryoncil®.
Product Launch and Approval: The company achieved FDA approval for Ryoncil®, the first FDA-approved mesenchymal stromal cell product in the U.S., specifically for treating steroid-refractory acute graft-versus-host disease in pediatric patients.
Future Developments: Mesoblast plans to expand Ryoncil®'s indications to adults with severe SR-aGvHD and inflammatory bowel diseases, alongside advancing other therapies like Revascor® for heart failure and rexlemestrocel-L for chronic low back pain.
Corporate Governance Enhancements: The Board of Directors was strengthened with new appointments, aiming to bolster the company's operational and financial strategies as it transitions into a commercial biotechnology firm.
MESO
$18.34+Infinity%1D
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 29.50 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 29.50 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.710
Low
24.00
Averages
29.50
High
35.00
Current: 17.710
Low
24.00
Averages
29.50
High
35.00
Jefferies
Hold
to
Buy
upgrade
$3
2025-11-25
Reason
Jefferies
Price Target
$3
2025-11-25
upgrade
Hold
to
Buy
Reason
Jefferies upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3.
Jefferies
David Stanton
Hold
to
Buy
upgrade
$3
2025-11-25
Reason
Jefferies
David Stanton
Price Target
$3
2025-11-25
upgrade
Hold
to
Buy
Reason
As previously reported, Jefferies analyst David Stanton upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3. Ryoncil continues to be rolled out and the firm forecasts 78 patients will complete therapy in FY26, up from 63, while updating its estimates for fiscal Q2 results and FY26 forecasts.
Jefferies
David Stanton
Buy
to
Hold
downgrade
2025-07-18
Reason
Jefferies
David Stanton
Price Target
2025-07-18
downgrade
Buy
to
Hold
Reason
Jefferies analyst David Stanton downgraded Mesoblast to Hold from Buy with a price target of A$2.60, up from A$2.50, following the fiscal Q4 report. The firm estimates 68 paid infusions were given during the quarter of Ryoncil in the U.S. with six patents likely having completed treatment. Jefferies updated fiscal 2025 estimates and awaits the company's annual results in August.
Piper Sandler
Edward Tenthoff
Buy
Reiterates
$15 → $24
2025-02-07
Reason
Piper Sandler
Edward Tenthoff
Price Target
$15 → $24
2025-02-07
Reiterates
Buy
Reason
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
